Prosecution Insights
Last updated: August 01, 2026

Examiner: SLOUP IV, RUDOLPH EDWARD

Tech Center 1600 • Art Units: 1645 1681

This examiner grants 100% of resolved cases

Performance Statistics

100.0%
Allow Rate
+40.0% vs TC avg
16
Total Applications
+0.0%
Interview Lift
951
Avg Prosecution Days
Based on 2 resolved cases, 2023–2026

Rejection Statute Breakdown

11.1%
§101 Eligibility
5.6%
§102 Novelty
50.0%
§103 Obviousness
5.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18034668 COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM Non-Final OA RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
18854288 HUMAN IGE MONOCLONAL ANTIBODIES TO PARASITIC WORM ANTIGENS AND USES THEREFOR Non-Final OA Vanderbilt University
18288634 NEW STABLE ANTI-VISTA ANTIBODY Non-Final OA PIERRE FABRE MEDICAMENT
18044349 METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES OR CONDITIONS RELATED TO INNATE LYMPHOID CELLS Non-Final OA NATIONAL JEWISH HEALTH
18555429 PESTICIDAL MINICELLS AND COMPOSITIONS THEREOF FOR AGRICULTURAL APPLICATIONS Non-Final OA Invaio Sciences, Inc.
18097111 NUTRITIONAL SUPPLEMENTS AND METHODS OF NUTRITIONAL SUPPLEMENTATION AFFECTING WEIGHT LOSS Non-Final OA Amare Global

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month